FFL Flash Alert - Coming off a so-so week 4, will Jonathan Taylor top 64.5 rush yards vs. Cleveland?
FFL Flash Alert - Coming off a so-so week 4, will Jonathan Taylor top 64.5 rush yards vs. Cleveland?
Bosnian police on Tuesday detained two Serb ex-soldiers accused of taking part in the murder of at least 78 Bosniak (Bosnian Muslim) civilians early in the Bosnian war of the 1990s, the state prosecution said in a statement. A quarter of a century after the U.S.-sponsored Dayton peace accords ended the war among Bosnian Serbs, Croats and Bosniaks in which about 100,000 people were killed, many war criminals are still at large in the ethnically divided country. Unčanin Boško, 51, and Despot Dragan, 56, are accused of violating the provisions of the Geneva conventions on the protection of civilians during wartime and of crimes against humanity, the prosecutor's office said.
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few...
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association. Currently, Amyloid-β buildup in the brain is believed to be the cause of Alzheimer’s among many researchers. There have been many attempts to prevent or reverse the disease by targeting Amyloid-β including the first vaccine clinical trial as AN-1792 in 2002 by Elan, which targeted Amyloid-β proteins. Unfortunately, the AN-1792 vaccine was suspended by FDA due to adverse effects. The long-term follow-up result to the vaccine responders demonstrated positive benefit from the vaccine, indicating that vaccine against Alzheimer’s disease with Aβ is promising if the treatment can overcome the adverse effects. The study, published in the Journal of Alzheimer’s Disease on October 15, 2020, shows that this novel vaccine, using immune cells known as dendritic cells loaded with a modified Aβ known as E22W42, could be a significant step in halting Alzheimer’s. Testing of this new vaccine was conducted on mice genetically engineered to develop high levels of Aβ and behavioral/cognitive abnormalities that mimic human Alzheimer’s disease, also known as transgenic1 mice. Testing has shown that all responders to the vaccine had slowed memory decline. Researchers compared two sets of mice; one set that was administered the vaccine and one set that was not, in a cognitive test called a “Radial Arm Water Maze”. This maze is composed of a large central area with six paths or “arms,” with a hidden escape platform found at the end of one of the arms. Mice were given a pass/fail depending on their ability to find the path with the hidden exit through a total of 15 trials. The results showed that the vaccinated mice showed fewer errors in working memory than the control transgenic mice, which showed a decrease in working memory like that seen in Alzheimer’s patients.On top of better performances in the water maze, the vaccinated mice were tested to have a higher level of Amyloid-β antibodies. Since antibodies function as the body's targeting system for foreign/unwanted materials, the antibodies will be responsible for breaking down the protein buildup, thus preventing neural degeneration.Previous vaccine attempts have failed in the clinical trial steps due to unwanted immune system side effects. Inflammation is a primary symptom of Alzheimer’s disease, so any possible treatment that causes neural inflammation as a side effect is essentially “pouring gas on a fire.” This is where the E22W42 vaccine shows one of its most important qualities. As described in the study, there was no significant difference in the quantity of immune elements that cause inflammation in the plasma of the vaccinated mice vs. the control mice. The researchers conclude that the E22W42 vaccine has little potential for over priming or otherwise inducing an adverse inflammatory reaction by the immune system. The predicted reason for the lack of inflammation is due to the vaccine being developed as a dendritic cell vaccine, acting as a natural adjuvant, as it uses dendritic cells to generate the antibodies. This is important as dendritic cells can induce a moderate amount of antibody response, thus helping to minimize adverse effects.“This therapeutic vaccine uses the body’s own immune cells to target the toxic Aβ molecules that accumulate harmfully in the brain. And, importantly, it provides strong immunomodulatory effects without inducing an unwanted, vaccine-associated autoimmune reaction in the aging mice. We are confident that this mutant-peptide sensitized dendritic cell vaccine can overcome all major adverse events of vaccines against Alzheimer’s disease and will bring great hope to Alzheimer’s disease patients once the vaccine is available to the public,” said Dr. Cao.In 2012, USF was granted a patent related to this technology (USPTO 8,188,046), and the patent has been exclusively licensed to Alzamend Neuro® (“Alzamend®” or the “Company”), a Tampa-based biotechnology company dedicated to finding a prevention, treatment and cure for Alzheimer’s disease. The Company’s goal is to move the technology out of preclinical testing and into human clinical trials during the first quarter of 2021 with the assistance of TAMM Net, Inc. (“TAMM Net”) a contract research organization located in Marietta, Georgia.“Our Company is committed to supporting the full product development life-cycle of treatment and cures for Alzheimer’s disease,” said Stephan Jackman, CEO of Alzamend Neuro®. “We believe that strong support of research is the foundation for true innovation, and we are excited to be working with Dr. Cao, the University of South Florida and TAMM Net to further develop E22W42 (also known as CAO22W or AL002) to alleviate the burden created by Alzheimer’s disease, the nation’s 6th leading cause of death and ‘most feared disease.’”“Modified cell therapies, especially dendritic cells, may provide a safer and more patient-specific active immunization. Ex-vivo modification of dendritic cells as a modality of treatment has been previously used in oncological therapeutics,” said Art Spalding, CEO of TAMM Net. “It has been shown to be relatively safe and is able to engage the immune system to attack the target tissues with success. Its use in Alzheimer’s therapeutics is relatively recent. We are excited to conduct a first-in-human phase 1 study of E22W42 in 2021.” __________________________ 1 The term “transgenic mice” refers to mice that have had DNA from another source put into their DNA. The foreign DNA is put into the nucleus of a fertilized mouse egg. This enables science to transform mice into those that mimic having certain attributes i.e. having dementia or Alzheimer’s disease.About Alzamend Neuro Alzamend Neuro®, Inc., (“Alzamend®)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend® is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. Alzamend® is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) from the preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend® has licensed both a patented mutant-peptide immunotherapeutic (AL002 or E22W42) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (AL001) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimer’s disease. With AL001 and AL002, the Company believes that we can change that.About TAMM Net, Inc. TAMM Net is a fully integrated contract research organization providing biomedical companies with expertise in; obtaining reimbursement, researching government funding resources, providing solutions to regulatory issues and applications, and supplying distribution to closed systems. Everyone on the TAMM Net team has over 20 years of experience in their fields with documented success.About USF Health USF Health (www.health.usf.edu) is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida’s Colleges of Medicine, Nursing, and Public Health; the Schools of Biomedical Sciences as well as Physical Therapy & Rehabilitation Sciences; and the USF Physicians Group. With more than $360 million in research grants and contracts last year, USF is one of the nation’s top 63 public research universities and one of 39 community-engaged, four-year public universities designated by the Carnegie Foundation for the Advancement of Teaching.About the Journal of Alzheimer’s Disease The Journal of Alzheimer’s Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 5.101 according to Thomson Reuters’ 2008 Journal Citation Reports. The Journal is published by IOS Press (http://www.iospress.nl).Forward-looking Statements Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are further qualified by other factors. The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.Contacts: Email: Info@Alzamend.com or call: 1-844-722-6333 Company Website: www.Alzamend.com Facebook: https://www.facebook.com/AlzamendNeuro/ Twitter: https://twitter.com/AlzamendNeuro Instagram: https://www.instagram.com/alzamendneuro/
The muscles and joints may not be the only parts of the body worn down by intense physical work.
* First Quarter Revenue of $13.2 million decreased 3% from the prior year; shortfall from expectations resulting from customer ordering patterns for flu-related mailback orders * Long-Term Care billings increased 110%; Pharmaceutical Manufacturer billings grew 26% * Retail market billings, excluding flu-related orders, up 26% * Route-Based Pickup billings increased 19% for the quarter * Billings in the Professional Market and Route-Based Pickup revenues recover to surpass pre-COVID-19 levels * New Pennsylvania autoclave increasing medical waste processing capacity from 18 to 27 million pounds per year and up from 10 million pounds a year ago * Strong December 2020 quarter expected for Retail, Pharmaceutical Manufacturer and Long-Term Care markets * Active pipeline of larger field sales opportunitiesHOUSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today reported financial results for the first quarter ended September 30, 2020.Revenue in the first quarter of fiscal 2021 was $13.2 million, a decrease of 3% compared to $13.6 million in the same prior year quarter. Customer billings decreased 6% to $13.4 million for the first quarter compared to $14.2 million for the same prior year quarter. GAAP revenue and customer billings were negatively impacted by the timing of flu and COVID-19 related mailback orders. Additionally, the Home Health Care market billings comparison was adversely impacted by a $0.9 million stocking order in the prior year related to a new distributor relationship.First quarter 2021 gross margin was 28% compared to 33% in the first quarter of fiscal 2020. The decrease in the gross margin was driven by the timing of flu and COVID-19 related mailback orders for the quarter. Without the impact from the shift in flu related orders, the first quarter 2021 gross margin would have been 32% to 33%. SG&A increased 8% to $3.8 million, or 29% of revenue, in the first quarter of fiscal 2021, as compared to SG&A of $3.5 million, or 26% of revenue, in the same prior year quarter. The increase in SG&A, which is consistent with our internal expectations, is related to the Company’s continued investments in sales and marketing.The Company reported an operating loss of $0.4 million in the first quarter of 2021, compared to operating income of $0.8 million in the first quarter of 2020. Sharps recorded net loss of $0.3 million, or a loss of $0.02 per basic and diluted share, in the first quarter of fiscal 2021, as compared to net income of $0.7 million, or $0.04 per basic and diluted share in the first quarter of fiscal 2020. Sharps recorded EBITDA of $0.1 million in the first quarter of fiscal 2021, compared to EBITDA of $1.2 million in the first quarter of fiscal 2020. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release).David P. Tusa, President and Chief Executive Officer of Sharps, stated, “During the first quarter we saw a significant rebound in our route-based business with revenues increasing 19% and surpassing pre-COVID-19 levels as well as our internal expectations. Likewise, Professional market billings have recovered and first quarter billings from this segment also exceeded pre-COVID-19 levels. This strength represents not only the resumption of operations for most of our COVID-19 affected customers but also reflects sales to new customers.“We have always viewed flu-related activity as a nine-month season, comprising the June, September and December quarters. Historically, order volumes, within the season, have often varied from quarter to quarter, depending upon customer ordering patterns and their distribution and warehouse facility operations which, this season, have been impacted by COVID-19. Accordingly, we experienced a shift in flu immunization and COVID-19 related orders from the September 2020 to the December quarter.“From our vantage point today, we remain confident that we’re in the midst of a very strong flu immunization season as evidenced by 50%+ increase in flu-related return mailbacks processed for August, September and October 2020. We are also hopeful that the flu immunization season could be followed by substantial activity related to a potential COVID-19 vaccine which many experts believe could be available later this year or early 2021. We have a robust inventory of our medical waste mailback solutions in place to meet anticipated strong demand and this month are commissioning a new autoclave online at our Pennsylvania facility, expanding our medical waste processing capacity from 18 million to 27 million pounds per year, which is up from 10 million pounds a year ago.“In addition to flu and potential COVID-19 vaccine related business, we remain keenly focused on landing larger route-based opportunities serviced by our expanded footprint which now serves 32 states, addressing 70% of the population. The pipeline of these opportunities is robust and very active, with prospects more engaged now than they were during the onset of the pandemic in March of 2020. Our goal is to close many of these opportunities in the December 2020 quarter, and begin generating revenue from these new contracts starting as early as the March 2021 quarter.”First Quarter ReviewRetail market billings decreased $0.5 million or 12% to $3.6 million in the first quarter of fiscal 2021 as compared to $4.1 million in the same prior year period. The decrease in retail billings is primarily due to, lower flu shot / COVID-19 related orders of $0.9 million due to the timing of related orders, partially offset by higher unused medication billings of $0.3 million from MedSafe and TakeAway Medication Recovery System envelopes. Excluding the flu-related billings, the Retail market billings increased 26%.Home Health Care market billings decreased 29% to $2.3 million in the first quarter of fiscal 2021 compared to $3.3 million in the first quarter of fiscal 2020. First quarter fiscal 2020 included a large stocking order of $0.9 million from a major healthcare distributor.Professional market billings of $4.1 million in the first quarter of fiscal 2021 were consistent with the same period of fiscal 2020. This market, which is comprised of physicians, clinics, dentists, surgery centers, labs, veterinarians and other healthcare providers, has recovered to billing levels higher than the March 2020 pre-pandemic time period, as most of the Company’s customer locations have reopened. Long-Term Care billings increased 110% to $1.3 million in the first quarter of fiscal 2021 compared to $0.6 million in the prior year period, related primarily to an increased volume of COVID-19 related waste management and ancillary supplies.Billings for the inside and online sales channel increased 13.3% to $2.9 million in the first quarter of fiscal 2021 as compared to $2.5 million in the same prior year period primarily due to increases in route-based pickup services to the long-term care and professional markets.Pharmaceutical Manufacturer billings increased 26% to $1.2 million in the first quarter of fiscal 2021 compared to $0.9 million in the first quarter of fiscal 2020, related to the timing of inventory builds for patient support programs.Financial Flexibility and a Strong Balance SheetCash was $6.8 million at September 30, 2020, compared to cash of $5.4 million at June 30, 2020. The Company had working capital of $10.1 million at September 30, 2020 compared to working capital of $11.1 at June 30, 2020.Mr. Tusa concluded, “We believe we have the opportunity to deliver a strong December 2020 quarter as a result of expected strength in Retail flu-related business, Long-Term Care market billings and Pharmaceutical Manufacturer market billings. Of greater importance is the opportunity to drive more revenue growth for fiscal year 2021 through the closing of larger field sales opportunities utilizing our expanded route-based infrastructure. We continue to provide uninterrupted service to our customers and thank our loyal and committed employees for their service to the Company and our customers during the pandemic.”First Quarter Fiscal Year 2021 Webcast and Conference CallThe Company will host a teleconference today beginning at 11:00 a.m. Eastern Time, during which management will review the financial and operating results for the period and discuss Sharps’ corporate strategy and outlook. A question-and-answer session will follow.The Sharps conference call can be accessed by domestic callers by dialing (877) 407-0782. International callers may access the call by dialing (201) 689-8567. The webcast can be monitored at www.sharpsinc.com. A telephonic replay will be available through November 26, 2020. To listen to the replay, domestic callers should dial (877) 481-4010 and international callers should dial (919) 882-2331 and enter replay ID number 38113. Transcript will also be posted to the Sharps website, once available. About Sharps Compliance Corp.Headquartered in Houston, Texas, Sharps Compliance is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Its key markets include healthcare facilities, pharmaceutical manufacturers, home healthcare providers, assisted living/long-term care, surgery centers, retail pharmacies and clinics, and the professional market which is comprised of physicians, dentists and veterinary practices. The Company's flagship product, the Sharps Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and other used healthcare materials. The Company also offers its route-based pick-up service in a thirty-two (32) state region of the South, Southeast, Midwest and Northeast portions of the United States. Sharps also provides two simple solutions for safe and easy disposal of unused medications: MedSafe collection receptacles and TakeAway Medication Recovery System Envelopes.More information on the Company and its products can be found on its website at: www.sharpsinc.com.Safe Harbor StatementThe information made available in this news release contains certain forward-looking statements which reflect Sharps Compliance Corp.'s current view of future events and financial performance. Wherever used, the words "estimate," "expect," "plan," "anticipate," "believe," "may" and similar expressions identify forward-looking statements. Any such forward-looking statements are subject to risks and uncertainties and the company's future results of operations could differ materially from historical results or current expectations. Some of these risks include, without limitation, the company's ability to educate its customers, development of public awareness programs to educate the identified consumer, customer preferences, the Company's ability to scale the business and manage its growth, the degree of success the Company has at gaining more large customer contracts, managing regulatory compliance and/or other factors that may be described in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and/or other filings with the Securities and Exchange Commission. Future economic and industry trends that could potentially impact revenue and profitability are difficult to predict. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results, express or implied therein, will not be realized.Non-GAAP MeasuresThis release contains certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”), including customer billings information and EBITDA. The Company believes this information is useful to investors and other interested parties. EBITDA is a significant performance metric used by management and by external users of our financial statements such as investors, research analysts and others to assess the financial performance of our assets without regard to financing methods, capital structure or historical cost basis; the ability of our assets to generate cash sufficient to pay interest costs and support our indebtedness; and our operating performance and return on capital as compared to those of other companies in our industry. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.For more information contact: Diana P. Diaz Sharps Compliance Corp. Vice President and Chief Financial Officer Phone: (713) 660-3547 Email: firstname.lastname@example.org John Nesbett/Jennifer Belodeau IMS Investor Relations Phone: (203) 972-9200 Email: email@example.com FINANCIAL TABLES FOLLOWSharps Compliance Corp. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited) Three-Months Ended September 30, 2020 2019% Change Revenue$13,151 $13,599 (3.3)% Cost of revenue9,528 9,115 4.5 % Gross profit3,623 4,484 (19.2)% Gross margin 27.5% 33.0% SG&A expense3,788 3,512 7.9 % Depreciation and amortization204 204 Operating Income (Loss)(369) 768 Operating margin(2.8)% 5.6% Interest income— 5 Interest expense(32) (19) Income associated with derivative instrument5 — Total other expense(27) (14) Income (loss) before income tax expense(396) 754 Income tax expense (benefit)(103) 68 Net Income (Loss)$(293) $686 Net Income (Loss) Per Share Basic and diluted$(0.02) $0.04 Weighted Average Shares Outstanding Basic16,391 16,145 Diluted16,391 16,168 Sharps Compliance Corp. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands) (Unaudited) September 30, June 30, 2020 2020 ASSETS: Current assets: Cash$6,785 $5,416 Accounts receivable, net10,629 11,789 Inventory5,476 5,638 Contract asset37 156 Prepaid and other current assets985 1,287 Total current assets23,912 24,286 Property, plant and equipment, net9,865 9,127 Operating lease right of use asset9,844 8,747 Inventory, net of current portion1,034 1,064 Other assets160 154 Goodwill6,735 6,735 Intangible assets, net2,667 2,771 Deferred tax asset1,355 1,252 Total assets$55,572 $54,136 LIABILITIES AND STOCKHOLDERS' EQUITY: Current liabilities Account payable$3,140 $3,291 Accrued liabilities2,738 2,833 Operating lease liability2,506 2,192 Current maturities of long-term debt2,091 1,658 Contract liability3,296 3,262 Total current liabilities13,771 13,236 Contract liability, net of current portion791 705 Operating lease liability, net of current portion7,493 6,671 Other liabilities417 441 Long-term debt, net of current portion3,428 3,505 Total liabilities25,900 24,558 Stockholders' equity29,672 29,578 Total liabilities and stockholders' equity$55,572 $54,136 Sharps Compliance Corp. and Subsidiaries Supplemental Customer Billing and Revenue Information (in thousands) (Unaudited) Three-Months Ended September 30, 2020 % Total 2019 $ Change % BILLINGS BY MARKET: Professional $4,133 30.8% $4,135 $(2) 0 % Retail 3,647 27.2% 4,142 (495) (12.0)% Home Health Care 2,348 17.5% 3,317 (969) (29.2)% Pharmaceutical Manufacturer 1,179 8.8% 937 242 25.8 % Long-Term Care 1,309 9.7% 624 685 109.8 % Government 515 3.8% 764 (249) (32.6)% Environmental 135 1.0% 19 116 610.5 % Other 162 1.2% 281 (119) (42.3)% Subtotal 13,428 100.0% 14,219 (791) (5.6)% GAAP Adjustment * (277) (620) 343 Revenue Reported $13,151 $13,599 $(448) (3.3)% *Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue. Customer billings include all invoiced amounts for products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales, (ii) recognition of certain revenue associated with product returned for treatment and destruction and (iii) provisions for certain product returns and discounts to customers which are accounted for as reductions in sales in the same period the related sales are recorded. Sharps Compliance Corp. and Subsidiaries Supplemental Customer Billing by Solution Information (in thousands) (Unaudited) Three-Months Ended September 30, 2020 % Total 2019 $ Change % BILLINGS BY SOLUTION: Mailbacks$6,439 47.9% $7,737 $(1,298) (16.8)% Route-Based Pickup3,156 23.5% 2,657 499 18.8 % Unused Medications2,361 17.6% 2,383 (22) (0.9)% Third Party Treatment135 1.0% 19 116 610.5 % Other 1,337 10.0% 1,423 (86) (6.0)% Total Billings by Solution$13,428 100.0% $14,219 $(791) (5.6)% Sharps Compliance Corp. and Subsidiaries Supplemental Customer Billing by Channel Information (in thousands) (Unaudited) Three-Months Ended September 30, 2020 % Total 2019 $ Change % Change BILLINGS BY CHANNEL: Direct Sales $7,018 52.2% $7,698 $(680) (8.8)% Distributions 3,543 26.4% 3,991 (448) (11.2)% Inside and Online Sales 2,867 21.4% 2,530 337 13.3% Total Billing by Channel $13,428 100.0 % $14,219 $(791) (5.6)% Sharps Compliance Corp. and Subsidiaries Supplemental Table to Reconcile Net Income to EBITDA* (in thousands) (Unaudited) Three-Months Ended September 30, 2020 2019 Net Income (Loss)$(293) $686 Income tax expense (benefit)(103) 68 Interest expense, net32 14 Depreciation and amortization423 421 EBITDA$59 $1,189 *The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income (loss), plus income tax expense (benefit), net interest expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity’s financial results, and accordingly, EBITDA should not be considered an alternative to operating income, net income, or cash flows as determined under generally accepted accounting principles and as reported by the Company.
Dollar General Announces November 13 Pre-Holiday Savings Event
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in patients 12 and older. The FDA is expected to make a decision in April 2021. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for abrocitinib in the same patient population with a decision anticipated in the second half of 2021.
Nestle told Reuters earlier this month that it has recently launched single-use sachets of Maggi seasonings in Indonesia and smaller sachets and cooking sauces in the Philippines. It also is promoting recipes that call for cheaper proteins like eggs and canned meat in the Philippines. "We'll give this (affordable products) more emphasis,” Nestle CEO Mark Schneider said last week after reporting third-quarter sales, “because affordability, especially when it comes to the economic consequences of COVID, will become ever more important."
As you might know, RLI Corp. (NYSE:RLI) just kicked off its latest quarterly results with some very strong numbers. It...
Chinese technology giant Ant Group has set the price for its initial public offering at an eye watering $34.4bn (£26.5bn) on the Shanghai and Hong Kong exchanges, making it the world’s largest stock market debut.
The "Electrocoating - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Fintech giant Square (NYSE: SQ) has allowed its Cash App customers to buy and sell bitcoin for some time now, and has some high-tech cryptocurrency initiatives underway. Here are the thoughts of Motley Fool analyst Jason Moser and Fool.com contributor Matthew Frankel, and what it might mean for shareholders. You know, we've got PayPal (NASDAQ: PYPL) with the Visa (NYSE: V) credit card, now we're talking about Square.
Two crew members of a Greek minesweeper were slightly hurt Tuesday after it collided with a Portuguese container ship off Piraeus, the port next to Athens, the navy said.
Eli Lilly & Co. shares fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a share, in the quarter, down from $1.254 billion, or $1.37 a share, in the year-earlier period. Adjusted per-share earnings came to $1.54, below the $1.71 FactSet consensus. Revenue rose 5% to $5.741 billion from $5.477 billion, but also lagged the $5.875 billion FactSet consensus. "Despite ongoing healthcare disruptions from the global pandemic, we remain confident in the strength of our underlying business and continue to manage our operations to deliver success over the long term," Chief Executive David A. Ricks said in a statement. The company is now expecting full-year EPS of $6.20 to $6.40 and adjusted EPS of $7.20 to $7.40. The FactSet consensus is for EPS of $7.28. Revenue is still expected to range from $23.7 billion to $24.2 billion, compared with a FactSet consensus of $23.9 billion. Shares have gained 8% in 2020, while the S&P 500 has gained 5%.
Dublin, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The "Specialty Fertilizers Market 2019-2024: Trends, Forecast, and Opportunity Analysis" report has been added to ResearchAndMarkets.com's offering. The global specialty fertilizers market is expected to grow with a CAGR of 7% from 2019 to 2024. The future of the specialty fertilizers market looks promising with opportunities in the agriculture sector. The major drivers for this market are technological advancements, increase in support of governments, growing population pool, increasing demand for food, and growing awareness regarding health care concerns. Some of the Specialty fertilizer companies profiled in this report include Yara International, Agrium Inc., Mosaic Company, ICL Fertilizers, Israel Chemical Limited, and Honeywell. Some of the features of 'Global Specialty Fertilizer Market 2019-2024: Trends, Forecast, and Opportunity Analysis' include * Market size estimates: Global specialty fertilizer market size estimation in terms of value ($M) shipment. * Trend and forecast analysis: Market trend (2013-2018) and forecast (2019-2024) by segments and region. * Segmentation analysis: Global market size by fertilizer type, intermediate type, crop type, and region. * Regional analysis: Global Specialty fertilizer market breakdown by North America, Europe, Asia Pacific, and the Rest of the World * Growth opportunities: Analysis on growth opportunities in different applications and regions for Specialty fertilizer in the global Specialty fertilizer market. * Strategic analysis: This includes M&A, new product development, and competitive landscape for specialty fertilizer in the global specialty fertilizer market. * Analysis of competitive intensity of the industry based on Porter's Five Forces model.This report answers the following 11 key questions: * Q.1.What are some of the most promising potential, high-growth opportunities for the global specialty fertilizers market? * Q.2.Which segments will grow at a faster pace and why? * Q.3.Which regions will grow at a faster pace and why? * Q.4.What are the key factors affecting market dynamics? What are the drivers and challenges of the specialty fertilizers market? * Q.5.What are the business risks and threats to the specialty fertilizers market? * Q.6.What are emerging trends in this specialty fertilizers market and the reasons behind them? * Q.7.What are some changing demands of customers in the specialty fertilizers market? * Q.8.What are the new developments in the specialty fertilizers market? Which companies are leading these developments? * Q.9.Who are the major players in this specialty fertilizers market? What strategic initiatives are being implemented by key players for business growth? * Q.10.What are some of the competitive products and processes in this specialty fertilizers area and how big of a threat do they pose for loss of market share via material or product substitution? * Q.11 What M & A activities have taken place in the last 5 years in this specialty fertilizers market?Key Topics Covered: 1\. Executive Summary 2\. Industry Background and Classifications 2.1: Introduction, Background, and Classification 2.2: Supply Chain 2.3: Industry Drivers and Challenges 3\. Market Trends and Forecast Analysis from 2013 to 2024: 3.1: Macroeconomic Trends and Forecast 3.2: Global Specialty Fertilizers Market: Trends and Forecast 3.3: Global Specialty Fertilizers Market By Fertilizer Type: 3.3.1: Water Soluble Fertilizers 3.3.2: Slow & Controlled Released Fertilizers 3.3.3: Micronutrient & Secondary Nutrient Fertilizers 3.3.4: Bio-stimulant Fertilizers 3.3.5: Stabilized Fertilizers 3.4: Global Specialty Fertilizers Market By Intermediate Type: 3.4.1: Monoammonium Phosphate 3.4.2: Monopotassium Phosphate 3.4.3: Potassium Nitrate 3.4.4: Potassium Sulfate 3.4.5: Potassium Chloride 3.4.6: Urea 3.4.7: Ammonium Nitrate 3.4.8: Phosphoric acid 3.4.9: Others 3.5: Global Specialty Fertilizers Market By Crop Type: 3.5.1: Cereals & Oilseeds 3.5.2: Fruits & Vegetables 3.5.3: Turf & Ornamentals 3.5.4: Others (pulses, sugar crops, fiber crops, and plantation crops) 4\. Market Trends and Forecast Analysis by Region: 4.1: Global Specialty Fertilizers Market by Region 4.2: North American Specialty Fertilizers Market 4.2.1: Market by Fertilizer Type: Water Soluble Fertilizers, Slow & Controlled Released Fertilizers, Micronutrient & Secondary Nutrient Fertilizers, Bio-stimulant Fertilizers, and Stabilized Fertilizers 4.2.2: Market by Intermediate Type: Monoammonium phosphate, monopotassium phosphate, potassium nitrate, potassium chloride, potassium sulfate, urea, ammonium nitrate, phosphoric acid, and others. 4.2.3: Market by Crop Type: Cereals & Oilseeds, Fruits & Vegetables, Turf & Ornamentals, and Others (pulses, sugar crops, fiber crops, and plantation crops) 4.2.4: Market by Country: US, Canada, and Mexico 4.3: European Specialty Fertilizers Market 4.4: APAC Specialty Fertilizers Market 4.5: ROW Specialty Fertilizers Market 5\. Competitor Analysis: 5.1: Product Portfolio Analysis 5.2: Market Share Analysis 5.3: Operational Integration 5.4: Geographical Reach 5.5: Porter's Five Forces Analysis 6\. Growth Opportunities and Strategic Analysis 6.1: Growth Opportunity Analysis 6.1.1: Growth Opportunities for Global Specialty Fertilizers Market by Fertilizer Type 6.1.2: Growth Opportunities for Global Specialty Fertilizers Market by Intermediate Type 6.1.3: Growth Opportunities for Global Specialty Fertilizers Market by Crop Type 6.1.4: Growth Opportunities for Global Specialty Fertilizers Market by Region 6.2: Emerging Trends in Global Specialty Fertilizers Market 6.3: Strategic Analysis 6.3.1: New Product Development 6.3.2: Capacity Expansion of Global Specialty Fertilizers Market 6.3.3: Mergers, Acquisitions and Joint Ventures in the Global Specialty Fertilizers Market 7\. Company Profiles of Leading Players: 7.1: Yara International 7.2: Agrium Inc. 7.3: Mosaic Company 7.4: ICL Fertilizers 7.5: Israel Chemical Limited 7.6: Honeywell For more information about this report visit https://www.researchandmarkets.com/r/r47uhtResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The Hollywood star said sister Deondra, who was 36, "is in heaven now dancing with her wings on".
"Tho my pain is unbelievable I smile when I think of all of the great memories that she left me," Foxx wrote in a heartbreaking tribute.
Belgium's federal government should decide by this weekend whether a return to a nationwide lockdown is required, as the country grapples with a resurgence in novel coronavirus cases and hospitals risk running out of beds, an official said. New infections in Belgium, among the hardest-hit countries in Europe, hit a peak of more than 18,000 on Oct. 20, almost a 10-fold increase from the high of a spring wave of the pandemic. Health Ministry spokesman Yves Van Laethem told Belgian broadcaster RTBF on Monday evening that a decision on returning to lockdown would need to be taken by the end of the week.
Firms are reportedly hiring fewer disabled applicants amid concerns about supporting them properly.
GOP needs in-person Florida early voters. Wisconsin court asked to rule on ballot misprints. No more stickers for Susan B. Anthony. Latest news.